Reframe Cancer joins GRiD

Driving awareness of cancer support

Jaskeet Briah
clock • 1 min read

Reframe Cancer has been named as a new member of industry body, Group Risk Development (GRiD), to drive knowledge and awareness of cancer support.

Reframe Cancer offers cancer navigation and whole of workplace care for employers and employees impacted by cancer. The cancer support provider works directly with employers and partners with insurers to deliver a personalised service to their customers affected by the disease. Cancer was once again the main cause of claims across all three types of group risk product last year, according to GRiD. The illness accounted for 68% of group critical illness claims, 39% of group life claims and 24% of group income protection claims. Mark Stephenson, chief executive officer, Reframe Cance...

To continue reading this article...

Join COVER for free

  • Unlimited access to real-time news, key trend analysis and industry insights.
  • Stay on top of the latest developments around health and wellbeing, diversity and inclusion and the cost of living crisis.
  • Receive breaking news stories straight to your inbox in the daily newsletter.
  • Members only access to monthly programme 'The COVER Review'
  • Be the first to hear about our CPD accredited events and awards programmes.

Join now

 

Already a Cover member?

Login

More on PMI

Six in 10 adults would choose PMI as top employer-funded benefit
PMI

Six in 10 adults would choose PMI as top employer-funded benefit

27% have self-funded treatment over the past five years

Jaskeet Briah
clock 10 September 2025 • 3 min read
Perci Health appoints medical director to support expansion
PMI

Perci Health appoints medical director to support expansion

Launch of new specialist clinics

Jaskeet Briah
clock 04 September 2025 • 2 min read
Private healthcare admissions hit second highest level in Q1 2025
PMI

Private healthcare admissions hit second highest level in Q1 2025

Insured admissions remain stable

Jaskeet Briah
clock 02 September 2025 • 3 min read